Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings)
Analysts' ratings for Roivant Sciences (NASDAQ:ROIV) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $30.25, with a high estimate of $33.00 and a low estimate of $26.00. Witnessing a positive shift, the current average has risen by 16.35% from the previous average price target of $26.00.
Decoding Analyst Ratings: A Detailed Look
The standing of Roivant Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yatin Suneja | Guggenheim | Raises | Buy | $30.00 | $28.00 |
| David Risinger | Leerink Partners | Raises | Outperform | $32.00 | $29.00 |
| Corinne Jenkins | Goldman Sachs | Raises | Buy | $33.00 | $24.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $26.00 | $23.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Roivant Sciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Roivant Sciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Roivant Sciences's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Roivant Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Roivant Sciences analyst ratings.
Get to Know Roivant Sciences Better
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences: A Financial Overview
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Roivant Sciences faced challenges, resulting in a decline of approximately -64.89% in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Roivant Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -7225.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Roivant Sciences's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Roivant Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.25%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.